We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results:1-10 of 211

Medicare further expands payment for and coverage of telehealth and similar services
  • Hogan Lovells
  • USA
  • November 7 2018

Through several recently published rules, the Centers for Medicare & Medicaid Services (CMS) is making it possible for Medicare beneficiaries to have


New anti-kickback prohibition in opioid bill creates tangled web of compliance obligations
  • Hogan Lovells
  • USA
  • October 9 2018

On October 3, the U.S. Congress passed H.R. 6, the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for


FDA schedules public hearing on solutions to drug shortages
  • Hogan Lovells
  • USA
  • October 8 2018

FDA schedules public hearing on solutions to drug shortages October 08, 2018 The U.S. Food and Drug Administration (FDA) has announced it will hold a


Measures of success: How value-based pricing may change the pharmaceutical industry
  • Hogan Lovells
  • USA
  • June 1 2017

Adoption of value-based pricing, where drug prices are linked to real-world outcomes rather than on a per-pill or per-treatment basis, will have a


“Double Dip” Effectively Approved by Center for Medicare and Medicaid Services
  • Hogan Lovells
  • USA
  • May 11 2017

Last week the Centers for Medicare and Medicaid Services (CMS) issued Release No. 104 to Manufacturers and Release No. 180, which invalidated earlier


CMS Request for Information Presents Rare Opportunity for Medicare Stakeholder Engagement
  • Hogan Lovells
  • USA
  • April 24 2017

On 14 April 2017, the Centers for Medicare & Medicaid Services (CMS) published the fiscal year (FY) 2018 Medicare Hospital Inpatient Prospective


What's the point? "Principal purpose" assessed immediately prior to transfer
  • Hogan Lovells
  • United Kingdom
  • March 13 2017

Various conditions have to be satisfied before there can be a service provision change under TUPE. In particular there has to be an organised


What’s in store for the Affordable Care Act and drug pricing policy under the Trump administration?
  • Hogan Lovells
  • USA
  • February 27 2017

The Trump administration has been vocal in its criticism of the Affordable Care Act (ACA), and already has worked with the Republican-controlled


Revisions to Clinical Data Publication Guidance extends scope of EMA disclosure power to clinical data submitted before 1 January 2015
  • Hogan Lovells
  • European Union
  • December 20 2016

On 9 December 2016, the European Medicines Agency (“EMA”) organised a webinar for industry associations. At the webinar, the EMA presented an update


New Belgian Innovation Office to Accelerate Availability of Novel Medicines
  • Hogan Lovells
  • European Union
  • December 14 2016

In July 2016, the Belgian Agency for Medicines and Healthcare Products (“FAMHP”) took steps to establish a National Innovation Office as part of the